Rua Bioscience has raised approximately NZ$1.0 million through its rights offer, well short of the NZ$2.8 million sought. The medicinal cannabis company says it still needs more working capital to fund inventory for its UK expansion.
- Approximately NZ$1.0 million raised against a NZ$2.8 million target
- 39,648,249 new shares subscribed, including oversubscriptions
- Remaining shortfall shares to be offered under NZX rules
- Additional funding may come from placement capacity or the Gisborne facility
- UK agreement expected to generate more than NZ$10 million over two years
Rights offer raises only part of targeted capital
Rua Bioscience Limited (NZX:RUA) has secured approximately NZ$1.0 million from its one-for-three renounceable rights offer, leaving the medicinal cannabis company well short of the NZ$2.8 million it sought. The result gives Rua fresh capital, but not enough to resolve the working-capital pressure identified by the board.
Eligible shareholders subscribed for 39,648,249 new shares, including oversubscriptions, equivalent to approximately 12% of the existing share base. Rua will now accept applications for the remaining shortfall shares under NZX Listing Rule 4.4. The new shares are expected to be allotted and begin trading on 21 October.
UK sales opportunity depends on further funding
The shortfall matters because Rua says it must fund inventory and working capital before sales from its UK distribution agreement arrive. The agreement, described by chair Anna Stove as the company’s largest export deal to date, is expected to generate more than NZ$10 million in revenue over two years.
That opportunity was one of the reasons Rua launched the capital raising, following its one-for-three rights offer, which was announced alongside concerns about the company’s ability to maintain sufficient cash. The current announcement does not say how much of the remaining shortfall has been committed, or whether any additional capital has already been secured.
Board flags placement and facility options
Stove said the company’s principal constraint was working capital rather than infrastructure. Rua is in discussions with existing shareholders who wanted to see the rights offer result before considering further commitments, while placement capacity could provide another funding route subject to shareholder approval at the annual shareholders’ meeting.
Rua is also pursuing options to realise value from its Gisborne manufacturing facility. The announcement gives no timing or valuation for a potential transaction, leaving the shortfall process and any subsequent funding commitments as the immediate tests of whether the company can support its planned UK rollout.
The commercial case rests on converting a forecast revenue opportunity into cash-generating sales without exhausting available capital first. With only approximately NZ$1.0 million raised and the company acknowledging that its working-capital requirements remain unmet, the next material signal will be whether further shareholders step in before inventory needs begin to build.
Bottom Line?
Rua has kept its UK growth plan alive, but the NZ$1.0 million raise leaves execution dependent on shortfall applications, new investor commitments or asset funding.
Questions in the middle?
- How many of the remaining shortfall shares will be taken up, and on what effective timetable?
- Will shareholders approve placement capacity at the annual meeting, and how much capital could it provide?
- Can Rua fund inventory for the UK agreement before the forecast revenue begins to arrive?